Busulphan
Immunodeficiencies
University of California, San FranciscoPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Immunodeficiencies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | BB |
Fludarabine Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | BB |
Thiotepa University of California, San Francisco | Phase 2 | BB |
HUMAN IMMUNOGLOBULINS Grifols Therapeutics LLC | Phase 3 | B |
Anti-Thymoglobulin, Rabbit New York Medical College | Phase 2 | B |
View all 23 →
Same molecule, other indications
Busulphan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →